124 related articles for article (PubMed ID: 1656362)
21. Genome-wide allelotyping of lung cancer identifies new regions of allelic loss, differences between small cell lung cancer and non-small cell lung cancer, and loci clustering.
Girard L; Zöchbauer-Müller S; Virmani AK; Gazdar AF; Minna JD
Cancer Res; 2000 Sep; 60(17):4894-906. PubMed ID: 10987304
[TBL] [Abstract][Full Text] [Related]
22. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.
Sekido Y; Bader S; Latif F; Gnarra JR; Gazdar AF; Linehan WM; Zbar B; Lerman MI; Minna JD
Oncogene; 1994 Jun; 9(6):1599-604. PubMed ID: 8183553
[TBL] [Abstract][Full Text] [Related]
23. Genomic organization and mutation analysis of Hel-N1 in lung cancers with chromosome 9p21 deletions.
Cairns P; Okami K; King P; Bonacum J; Ahrendt S; Wu L; Mao L; Jen J; Sidransky D
Cancer Res; 1997 Dec; 57(23):5356-9. PubMed ID: 9393760
[TBL] [Abstract][Full Text] [Related]
24. Alterations in novel candidate tumor suppressor genes, ING1 and ING2 in human lung cancer.
Okano T; Gemma A; Hosoya Y; Hosomi Y; Nara M; Kokubo Y; Yoshimura A; Shibuya M; Nagashima M; Harris CC; Kudoh S
Oncol Rep; 2006 Mar; 15(3):545-9. PubMed ID: 16465410
[TBL] [Abstract][Full Text] [Related]
25. p53 mutations, ras mutations, and p53-heat shock 70 protein complexes in human lung carcinoma cell lines.
Lehman TA; Bennett WP; Metcalf RA; Welsh JA; Ecker J; Modali RV; Ullrich S; Romano JW; Appella E; Testa JR
Cancer Res; 1991 Aug; 51(15):4090-6. PubMed ID: 1855224
[TBL] [Abstract][Full Text] [Related]
26. p53 mutations in ovarian cancer: a late event?
Mazars R; Pujol P; Maudelonde T; Jeanteur P; Theillet C
Oncogene; 1991 Sep; 6(9):1685-90. PubMed ID: 1923532
[TBL] [Abstract][Full Text] [Related]
27. p53 alterations in plutonium-induced F344 rat lung tumors.
Kelly G; Stegelmeier BL; Hahn FF
Radiat Res; 1995 Jun; 142(3):263-9. PubMed ID: 7761575
[TBL] [Abstract][Full Text] [Related]
28. Gender differences in p53 mutational status in small cell lung cancer.
Tseng JE; Rodriguez M; Ro J; Liu D; Hong WK; Mao L
Cancer Res; 1999 Nov; 59(22):5666-70. PubMed ID: 10582680
[TBL] [Abstract][Full Text] [Related]
29. Molecular analysis of the HuD gene encoding a paraneoplastic encephalomyelitis antigen in human lung cancer cell lines.
Sekido Y; Bader SA; Carbone DP; Johnson BE; Minna JD
Cancer Res; 1994 Sep; 54(18):4988-92. PubMed ID: 8069866
[TBL] [Abstract][Full Text] [Related]
30. Genetic analysis of human esophageal tumors from two high incidence geographic areas: frequent p53 base substitutions and absence of ras mutations.
Hollstein MC; Peri L; Mandard AM; Welsh JA; Montesano R; Metcalf RA; Bak M; Harris CC
Cancer Res; 1991 Aug; 51(15):4102-6. PubMed ID: 1855226
[TBL] [Abstract][Full Text] [Related]
31. p53 gene mutations in non-small cell lung cancer from Thai patients.
Petmitr S; Makthiengtrong S; Sutinont P; Migasena P
J Med Assoc Thai; 1999 Mar; 82(3):250-5. PubMed ID: 10410479
[TBL] [Abstract][Full Text] [Related]
32. Aberrant upregulation of a novel integrin alpha subunit gene at 3p21.3 in small cell lung cancer.
Hibi K; Yamakawa K; Ueda R; Horio Y; Murata Y; Tamari M; Uchida K; Takahashi T; Nakamura Y; Takahashi T
Oncogene; 1994 Feb; 9(2):611-9. PubMed ID: 8290272
[TBL] [Abstract][Full Text] [Related]
33. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
34. P53 mutations in mammary tumor cell lines and corresponding tumor tissues in the dog.
Van Leeuwen IS; Hellmèn E; Cornelisse CJ; Van den Burgh B; Rutteman GR
Anticancer Res; 1996; 16(6B):3737-44. PubMed ID: 9042250
[TBL] [Abstract][Full Text] [Related]
35. A nonsense mutation (Arg-196-Term) in exon 6 of the human TP53 gene identified in small cell lung carcinoma.
Hayes VM; Oosthuizen CJ; Kotze MJ; Marx MP; Buys CH
Mol Cell Probes; 1996 Oct; 10(5):393-5. PubMed ID: 8910896
[TBL] [Abstract][Full Text] [Related]
36. Interleukin-8 in non-small cell lung carcinoma: relation with angiogenic pattern and p53 alterations.
Boldrini L; Gisfredi S; Ursino S; Lucchi M; Mussi A; Basolo F; Pingitore R; Fontanini G
Lung Cancer; 2005 Dec; 50(3):309-17. PubMed ID: 16125276
[TBL] [Abstract][Full Text] [Related]
37. In situ detection of unexpected patterns of mutant p53 gene expression in non-small cell lung cancers.
Ebina M; Martínez A; Birrer MJ; Ilona Linnoila R
Oncogene; 2001 May; 20(20):2579-86. PubMed ID: 11420668
[TBL] [Abstract][Full Text] [Related]
38. P53 and K-ras mutations are frequent events in microscopically negative surgical margins from patients with nonsmall cell lung carcinoma.
Jassem J; Jassem E; Jakóbkiewicz-Banecka J; Rzyman W; Badzio A; Dziadziuszko R; Kobierska-Gulida G; Szymanowska A; Skrzypski M; Zylicz M
Cancer; 2004 May; 100(9):1951-60. PubMed ID: 15112277
[TBL] [Abstract][Full Text] [Related]
39. Mutations in p53 are frequent in the preneoplastic stage of mouse mammary tumor development.
Jerry DJ; Ozbun MA; Kittrell FS; Lane DP; Medina D; Butel JS
Cancer Res; 1993 Jul; 53(14):3374-81. PubMed ID: 8324748
[TBL] [Abstract][Full Text] [Related]
40. Base transitions are the most frequent genetic changes at P53 in gastric cancer.
Renault B; van den Broek M; Fodde R; Wijnen J; Pellegata NS; Amadori D; Khan PM; Ranzani GN
Cancer Res; 1993 Jun; 53(11):2614-7. PubMed ID: 8495424
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
